drugset / Trial / NCT00757250
Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety of an investigational medication, TXA127, and its ability to increase T-lymphocyte counts, specifically CD4+ T-lymphocytes, in persons infected with human immunodeficiency virus who are taking highly active anti-retroviral therapy.
Timeline
- Start
- 2008-09
- Primary completion
- 2011-12
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | talfirastide | Peptide | 50 ug/kg | Subcutaneous |
| Subject | talfirastide | Peptide | 100 ug/kg | Subcutaneous |
| Subject | talfirastide | Peptide | 200 ug/kg | Subcutaneous |
| Subject | talfirastide | Peptide | 300 ug/kg | Subcutaneous |